INHBA and breast neoplasm: Therefore, the development of therapeutic strategies using small molecule inhibitors against Activin receptors or neutralizing antibodies targeting Activin A ligand, could be used as an alternative approach for breast tumors overexpressing INHBA and/or IL13Rα2.